BioCentury | Jun 8, 2015
Company News

Santen sales and marketing update

...Care (IQWiG) said that added benefit cannot be derived for the fixed combination of Tapcom tafluprost/timolol...
BioCentury | May 19, 2014
Company News

Merck, Santen deal

...PF, a preservative-free formulation of Timoptic; Timoptic XE, a gel-forming formulation of Timoptic; and Saflutan tafluprost...
...$52.8 million in cash. Earlier this year, Akorn acquired U.S. rights to ophthalmic drug Zioptan tafluprost...
...PF, a preservative-free formulation of Timoptic; Timoptic XE, a gel-forming formulation of Timoptic; and Saflutan tafluprost...
BioCentury | May 14, 2014
Company News

Merck divests Europe, Asia rights for ophthalmic products to Santen

...$52.8 million in cash. Earlier this year, Akorn acquired U.S. rights to ophthalmic drug Zioptan tafluprost...
BioCentury | Dec 16, 2013
Strategy

Out in the cold

...Bayer Both Staxyn orodispersible vardenafil Bayer/GSK Express Scripts Prostaglandins (glaucoma) Lumigan bimatoprost Allergan CVS Zioptan tafluprost...
BioCentury | Oct 14, 2013
Strategy

Reviving Merck

...1H13. Merck doesn't break out sales for the other three, which include glaucoma drug Zioptan tafluprost...
BioCentury | Jan 7, 2013
Finance

Buyside View XXI: Sunny side up

...Tokyo:4503) Xtandi enzalutamide Metastatic castration-resistant prostate cancer (CRPC) U.S. Merck & Co. Inc. (NYSE:MRK) Zioptan tafluprost...
BioCentury | Apr 2, 2012
Finance

Doubling down

...KOSDAQ:078160) Korea approves Cartistem to treat osteoarthritis Merck & Co. Inc. (NYSE:MRK) FDA approves Zioptan tafluprost...
BioCentury | Feb 20, 2012
Clinical News

Zioptan tafluprost regulatory update

...FDA approved Zioptan tafluprost from Merck to treat elevated intraocular pressure (IOP) in patients with open-angle...
...Japan Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Zioptan tafluprost ( DE-085 , MK-2452...
BioCentury | Feb 14, 2012
Company News

FDA approves Merck's tafluprost

...FDA approved Zioptan tafluprost from Merck & Co. Inc. (NYSE:MRK) to treat elevated intraocular pressure (IOP...
BioCentury | Nov 14, 2011
Clinical News

Tafluprost regulatory update

...Merck received a complete response letter from FDA for an NDA for tafluprost to treat elevated...
...did not disclose details of the letter, said it plans to discuss it with FDA. Tafluprost...
...Osaka, Japan Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Tafluprost ( DE-085 , MK-2452...
Items per page:
1 - 10 of 21